TICKERNERD
Menu
ACRVACRVHealthcare · Biotechnology

ACRV Stock Forecast: Acrivon Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$1.76
−1.68% on the day

The 7 Wall Street analysts covering Acrivon Therapeutics, Inc. hold a median 12-month price target of $11 — +496.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 28 Oct 2026 — in the upper half.

Market cap
$76.7M
Ticker Nerd rank
66/ 100
Median analyst target
$11
Analysts covering
7
Revenue$0.0
Operating income−$18.7M
Net income−$18.0M
Free cash flow−$14.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
0.0%
1M
−15.4%
YTD
−27.0%
1Y
−6.9%
From 52W high
−41.5%
From 52W low
+36.4%
$1.29
$3.01
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACRV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Acrivon Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
66/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
78
Size
76
Revisions
69
Growth
69
Momentum
58
Issuance
46
Quality
45
Volatility
45
Value
21

Accruals (78): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (21): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ACRV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACRV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26ACRVHigh $19Median $11Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $7Median $11High $19

The green dot is the last close — the median target sits +496.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Jan 2026Piper SandlerMaintainsOverweight$6.00 → $8.00
25 Nov 2025HC Wainwright & Co.ReiteratesBuy—
14 Aug 2025OppenheimerMaintainsOutperform—
16 May 2025Jones TradingDowngradeHold—
15 May 2025OppenheimerMaintainsOutperform—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025OppenheimerMaintainsOutperform—
26 Mar 2025Cantor FitzgeraldReiteratesOverweight—
26 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
26 Mar 2025HC Wainwright & Co.MaintainsBuy—
31 Jan 2025Cantor FitzgeraldInitiatesOverweight—
14 Nov 2024BMO CapitalMaintainsOutperform—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright& Co.ReiteratesBuy—
16 Sept 2024BMO CapitalReiteratesOutperform—
16 Sept 2024HC Wainwright & Co.ReiteratesBuy—
16 Sept 2024JMP SecuritiesReiteratesMarket Outperform—
16 Sept 2024Ladenburg ThalmannUpgradeBuy—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—
15 May 2024BMO CapitalReiteratesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ACRV appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ACRV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Acrivon Therapeutics, Inc. returned −6.9% against +13.1% for the S&P 500, dividends included.

ACRV vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140Jan 26Apr 26Jul 26Oct 26ACRVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACRV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Acrivon Therapeutics, Inc. (ACRV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.9×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
0.9×

Cheaper than 73% of US stocks

EV / EBITDA
0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−64.6%

Higher than 18% of US stocks

Return on assets
−38.0%

Higher than 11% of US stocks

Dividend yield
92.7%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Acrivon Therapeutics, Inc. (ACRV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Acrivon Therapeutics, Inc. has a market value of $76.7M and an enterprise value of −$11.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$74.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$64.1M.

  • Shares outstanding: 42.8M.

  • Trailing P/E: −0.9×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 92.65%, paying out 0% of earnings.

  • Acrivon Therapeutics, Inc. employs 74 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

ACRV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACRVAcrivon Therapeutics, Inc.$76.7M66
OKYOOKYO Pharma Ltd.$76.5M28
CINGCingulate, Inc.$76.3M42
NTRBNutriband, Inc.$77.8M36
CRBPCorbus Pharmaceuticals Holdings, Inc.$78.7M18
TELOTelomir Pharmaceuticals, Inc.$74.4M30
MNOVMediciNova, Inc.$72.2M97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Acrivon Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACRV news & analysis

Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium

GlobeNewsWire · 29 Oct 2026positive

Acrivon said early Phase 1/2 dose-escalation results for ACR-2316 will be presented in a late-breaking oral plenary at the 38th EORTC-NCI-AACR Symposium on November 20, 2026. The company reported confirmed complete and partial responses in heavily pretreated AP3-predicted tumors, activity in K-Ras pathway-mutated cancers, and a favorable safety profile to date.

Why it matters — The reported clinical activity and safety findings, along with plans to expand the study to pancreatic cancer and explore combinations, are relevant to observers tracking ACRV’s ACR-2316 program.

Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

GlobeNewsWire · 20 Oct 2026positive

Acrivon announced that it has advanced ACR-7280, an oral CDK11 inhibitor selected from AP3-discovered candidates, toward development. The company said the candidate showed complete tumor regression in aggressive AML xenograft models and that IND-enabling studies are ongoing, with an IND submission on track for the first half of 2027.

Why it matters — The update outlines a new development candidate and its preclinical findings, as well as Acrivon’s stated timeline toward an IND submission.

What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock

Zacks Investment Research · 15 Sept 2026positive

Acrivon Therapeutics, Inc. (ACRV) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade suggests the stock might move higher based on this improved outlook.

Why it matters — A Zacks Rank upgrade signals improved expectations for the company's earnings, which ACRV watchers would consider a favorable development for the stock.

Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?

Zacks Investment Research · 3 Sept 2026neutral

Acrivon Therapeutics' stock reached a key technical support level as its 50-day simple moving average crossed above its 200-day simple moving average, a pattern known as a "golden cross." The development was highlighted in a Zacks Investment Research report.

Why it matters — ACRV watchers may note this technical signal as an indicator of a potential shift in the stock's short-term and long-term momentum trend.

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

GlobeNewsWire · 2 Sept 2026neutral

Acrivon Therapeutics, a clinical stage biotechnology company developing precision medicines with its proprietary AP3 platform, announced that its president and CEO, Peter Blume-Jensen, will present at the 2026 Cantor Global Healthcare Conference.

Why it matters — The company leadership's participation at a major healthcare conference provides an opportunity for investors and industry observers to hear directly about Acrivon's progress and strategy.

FAQ

Frequently asked questions about ACRV stock

What is the ACRV stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Acrivon Therapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $7 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACRV stock a buy right now?

Of the 7 analysts covering Acrivon Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Acrivon Therapeutics, Inc. 66 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACRV?

As at 28 Oct 2026, Acrivon Therapeutics, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (78 of 100).

Will ACRV stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +496.6% from the last close, and Ticker Nerd's factor model ranks Acrivon Therapeutics, Inc. 66 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACRV stock forecast for 2030?

No analyst covering Acrivon Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACRV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $19 over the next 12 months.

How has ACRV stock performed over the past year?

Acrivon Therapeutics, Inc. returned -6.9% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Acrivon Therapeutics, Inc. do?

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology.

What is the latest news on ACRV?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium". Acrivon said early Phase 1/2 dose-escalation results for ACR-2316 will be presented in a late-breaking oral plenary at the 38th EORTC-NCI-AACR Symposium on November 20, 2026. The company reported confirmed complete and partial responses in heavily pretreated AP3-predicted tumors, activity in K-Ras pathway-mutated cancers, and a favorable safety profile to date.

Company

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops cancer medicines using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which is designed to match drug mechanisms with the biological drivers of each tumor and identify patients most likely to respond. Its current work centers on targeted therapies and companion diagnostics for solid tumors, with programs spanning DNA damage response and cell-cycle regulation pathways. Acrivon Therapeutics also develops its OncoSignature diagnostic approach to support patient selection in clinical development. Headquartered in Watertown, Massachusetts, Acrivon Therapeutics plays a specialized role in the biopharmaceutical market by combining drug discovery, biomarker development, and clinical research to advance more selective oncology treatments.

CEO Dr. Peter Blume-Jensen M.D., Ph.D. · 74 employees · United States · https://acrivon.com